In vivo evaluation of cetuximab-conjugated poly(γ-glutamic acid)-docetaxel nanomedicines in EGFR-overexpressing gastric cancer xenografts [Corrigendum]

This article refers to:

In vivo evaluation of cetuximab-conjugated poly(γ-glutamic acid)-docetaxel nanomedicines in EGFR-overexpressing gastric cancer xenografts

Sreeranganathan M, Uthaman S, Sarmento B, et al. Int J Nanomedicine. 2017;12:7165–7182.

When reviewing the paper, the authors noted some errors in Figure 2E (page 7171) and Figure 6 (page 7176). They confirm that the corrections to Figures 2 and 6 do not alter the inferences or conclusion of the respective figures, nor the overall conclusion of the article, and apologize for this inadvertent error.

In the original manuscript, Figure 2 represents the cellular internalization of the nanoparticles and Figure 2E represents the uptake of targeted nanoparticles by MKN-28 cells at a higher magnification. In Figure 2E, the fluorescence image was wrongly merged with the incorrect brightfield image of the cell. The authors have rectified this mistake by replacing Figure 2E with the confocal microscope image using the correct phase contrast, fluorescent, and merged images. The corrected version of Figure 2 is included as follows.

Figure 2 Cellular uptake analysis.

Figure 6 indicated the qualitative evaluation of tumor accumulation of nontargeted (Figure 6A) and targeted (Figure 6B) nanoparticles. In these figures, fluorescent images were overlaid incorrectly on the same base nonfluorescent image of the mice, resulting in image repetition. This mistake has been rectified by overlaying correct fluorescent and base images of mice. Accordingly, the mean fluorescence intensity graph, Figure 6C, has also been corrected. The corrected version of Figure 6 is included as follows.

Figure 6 Qualitative biodistribution analysis using in vivo imaging in gastric cancer xenografts (n=3).